Endocrinology and Metabolism

Myung-Chul Lee (Lee MC)

2 Articles

Clinical Study
Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer: Myung-Chul Lee, Min Joo Kim, Hoon Sung Choi, Sun Wook Cho, Guk Haeng Lee, Young Joo Park, Do Joon Park; Endocrinol Metab. 2019;34(2):150-157. Published online May 10, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.2.150

6,698 View
137 Download
28 Web of Science
31 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Thyroid-stimulating hormone (TSH) suppression is recommended for patients who undergo thyroidectomy for differentiated thyroid cancer (DTC). However, the impact of TSH suppression on clinical outcomes in low-risk DTC remains uncertain. Therefore, we investigated the effects of postoperative TSH levels on recurrence in patients with low-risk DTC after thyroid lobectomy.

Methods

Patients (n=1,528) who underwent thyroid lobectomy for papillary thyroid carcinoma between 2000 and 2012 were included in this study. According to the mean and dominant TSH values during the entire follow-up period or 5 years, patients were divided into four groups (<0.5, 0.5 to 1.9, 2.0 to 4.4, and ≥4.5 mIU/L). Recurrence-free survival was compared among the groups.

Results

During the 5.6 years of follow-up, 21 patients (1.4%) experienced recurrence. Mean TSH levels were within the recommended low-normal range (0.5 to 1.9 mIU/L) during the total follow-up period or 5 years in 38.1% or 36.0% of patients. The mean and dominant TSH values did not affect recurrence-free survival. Adjustment for other risk factors did not alter the results.

Conclusion

Serum TSH levels did not affect short-term recurrence in patients with low-risk DTC after thyroid lobectomy. TSH suppression should be conducted more selectively.

Citations

Citations to this article as recorded by

Dynamic risk assessment in patients with differentiated thyroid cancer
Erika Abelleira, Fernando Jerkovich
Reviews in Endocrine and Metabolic Disorders.2024; 25(1): 79. CrossRef
Stimulating thyroglobulin to TSH ratio predict long-term efficacy of 131I therapy in patients with differentiated thyroid cancer after total thyroidectomy: a retrospective study
Xue Yin, Chao Lu, Danyang Sun, Yanhui Ji, Yan Wang, Hongyuan Zheng, Ziyu Ma, Qiang Jia, Jian Tan, Wei Zheng
Endocrine.2024;[Epub] CrossRef
Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study)
Ja Kyung Lee, Eu Jeong Ku, Su-jin Kim, Woochul Kim, Jae Won Cho, Kyong Yeun Jung, Hyeong Won Yu, Yea Eun Kang, Mijin Kim, Hee Kyung Kim, Junsun Ryu, June Young Choi
Annals of Surgical Treatment and Research.2024; 106(1): 19. CrossRef
Impact of a mobile health intervention based on multi-theory model of health behavior change on self-management in patients with differentiated thyroid cancer: protocol for a randomized controlled trial
Yang Jiang, Xiangju Sun, Maomin Jiang, Hewei Min, Jing Wang, Xinghua Fu, Jiale Qi, Zhenjie Yu, Xiaomei Zhu, Yibo Wu
Frontiers in Public Health.2024;[Epub] CrossRef
Risk of Subsequent Primary Cancers in Thyroid Cancer Survivors according to the Dose of Levothyroxine: A Nationwide Cohort Study
Min-Su Kim, Jang Won Lee, Min Kyung Hyun, Young Shin Song
Endocrinology and Metabolism.2024; 39(2): 288. CrossRef
Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer
Arash Abiri, Khodayar Goshtasbi, Sina J. Torabi, Edward C. Kuan, William B. Armstrong, Tjoson Tjoa, Yarah M. Haidar
Otolaryngology–Head and Neck Surgery.2023; 168(4): 745. CrossRef
Outcomes of Patients with an Intermediate‐Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma
Kiyomi Horiuchi, Mikiko Fujimoto, Kamio Hidenori, Yusaku Yoshida, Eiichiro Noguchi, Yoko Omi, Takahiro Okamoto
World Journal of Surgery.2023; 47(10): 2464. CrossRef
Effects of Isthmus Preservation on Postoperative Hypothyroidism after Lobectomy
Yeong San Jeon, Wan Wook Kim
International Journal of Thyroidology.2023; 16(1): 120. CrossRef
Physical activity and reduced risk of fracture in thyroid cancer patients after thyroidectomy — a nationwide cohort study
Jinyoung Kim, Kyungdo Han, Jin-Hyung Jung, Jeonghoon Ha, Chaiho Jeong, Jun-Young Heu, Se-Won Lee, Jeongmin Lee, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Ki-Hyun Baek
Frontiers in Endocrinology.2023;[Epub] CrossRef
Association between thyroid stimulating hormone levels and papillary thyroid cancer risk: A meta-analysis
Bin Xu, Shu-Yan Gu, Ning-Ming Zhou, Jun-Jie Jiang
Open Life Sciences.2023;[Epub] CrossRef
The Relationship between Thyrotropin Serum Concentrations and Thyroid Carcinoma
Xueqi Zhang, Lijun Tian, Di Teng, Weiping Teng
Cancers.2023; 15(20): 5017. CrossRef
Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy
Benjamin J. Gigliotti, Sina Jasim
Endocrine.2023; 83(2): 251. CrossRef
Optimal Serum Thyrotropin Level for Patients with Papillary Thyroid Carcinoma After Lobectomy
Siyuan Xu, Ying Huang, Hui Huang, Xiaohang Zhang, Jiaxin Qian, Xiaolei Wang, Zhengang Xu, Shaoyan Liu, Jie Liu
Thyroid.2022; 32(2): 138. CrossRef
Optimal Thyrotropin Following Lobectomy for Papillary Thyroid Cancer: Does It Exist?
Lindsay Bischoff, Megan R. Haymart
Thyroid.2022; 32(2): 117. CrossRef
Evaluation of ITGA3 as a Biomarker of Progression and Recurrence in Papillary Thyroid Carcinoma
Guoliang Zhang, Bing Li, Yuanmei Lin
Frontiers in Oncology.2022;[Epub] CrossRef
The Question of an Optimal TSH Goal After Lobectomy for Papillary Thyroid Cancer
Bernadette Biondi
Clinical Thyroidology.2022; 34(2): 67. CrossRef
Is Maintaining Thyroid-Stimulating Hormone Effective in Patients Undergoing Thyroid Lobectomy for Low-Risk Differentiated Thyroid Cancer? A Systematic Review and Meta-Analysis
Ho-Ryun Won, Eonju Jeon, Jae Won Chang, Yea Eun Kang, Kunho Song, Sun Wook Kim, Dong Mee Lim, Tae Kwun Ha, Ki-Wook Chung, Hyo-Jeong Kim, Young Joo Park, Bon Seok Koo
Cancers.2022; 14(6): 1470. CrossRef
Research Review of Thermal Ablation in the Treatment of Papillary Thyroid Carcinoma
Di Ou, Chen Chen, Tian Jiang, Dong Xu
Frontiers in Oncology.2022;[Epub] CrossRef
CACA guidelines for holistic integrative management of thyroid cancer
Minghua Ge, Ming Gao, Ruochuan Cheng, Xiaohong Chen, Haixia Guan, Yansong Lin, Shaoyan Liu, Yu Wang, Chuanming Zheng, Xiangqian Zheng
Holistic Integrative Oncology.2022;[Epub] CrossRef
Value of thyroglobulin post hemithyroidectomy for cancer: a literature review
Saam S. Tourani, Bill Fleming, Justin Gundara
ANZ Journal of Surgery.2021; 91(4): 724. CrossRef
Pros and cons of hemi‐thyroidectomy for low‐risk differentiated thyroid cancer
Alexander J. Papachristos, Anthony Glover, Mark S. Sywak, Stan B. Sidhu
ANZ Journal of Surgery.2021; 91(9): 1704. CrossRef
Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review
Carla GAMBALE, Rossella ELISEI, Antonio MATRONE
Minerva Endocrinologica.2021;[Epub] CrossRef
The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study
Yi Dou, Yingji Chen, Daixing Hu, Xinliang Su
Frontiers in Endocrinology.2021;[Epub] CrossRef
Controversy: For or against thyroid lobectomy in > 1 cm differentiated thyroid cancer?
Fabrice Menegaux, Jean-Christophe Lifante
Annales d'Endocrinologie.2021; 82(2): 78. CrossRef
Thyroid cancer, recent advances in diagnosis and therapy
Fadi Nabhan, Priya H. Dedhia, Matthew D. Ringel
International Journal of Cancer.2021; 149(5): 984. CrossRef
A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol
Eun Kyung Lee, Yea Eun Kang, Young Joo Park, Bon Seok Koo, Ki-Wook Chung, Eu Jeong Ku, Ho-Ryun Won, Won Sang Yoo, Eonju Jeon, Se Hyun Paek, Yong Sang Lee, Dong Mee Lim, Yong Joon Suh, Ha Kyoung Park, Hyo-Jeong Kim, Bo Hyun Kim, Mijin Kim, Sun Wook Kim, Ka
Endocrinology and Metabolism.2021; 36(3): 574. CrossRef
Long-term follow-up results of PTMC treated by ultrasound-guided radiofrequency ablation: a retrospective study
Yalin Zhu, Ying Che, Shuhang Gao, Shuangsong Ren, Mengying Tong, Lina Wang, Fang Yang
International Journal of Hyperthermia.2021; 38(1): 1225. CrossRef
Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up
Soo Young Kim, Hee Jun Kim, Seok-Mo Kim, Hojin Chang, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park
Frontiers in Endocrinology.2020;[Epub] CrossRef
Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
Dana M. Hartl, Joanne Guerlain, Ingrid Breuskin, Julien Hadoux, Eric Baudin, Abir Al Ghuzlan, Marie Terroir-Cassou-Mounat, Livia Lamartina, Sophie Leboulleux
Cancers.2020; 12(11): 3282. CrossRef
Annual Neck Ultrasonography Surveillance between 3 to 12 Years after Thyroid Lobectomy for Papillary Thyroid Microcarcinoma
Jin Gu Kang, Jung Eun Choi, Soo Jung Lee, Su Hwan Kang
International Journal of Thyroidology.2020; 13(2): 142. CrossRef
Thyroid hormone therapy in differentiated thyroid cancer
Giorgio Grani, Valeria Ramundo, Antonella Verrienti, Marialuisa Sponziello, Cosimo Durante
Endocrine.2019; 66(1): 43. CrossRef

Preoperative Localization and Intraoperative Parathyroid Hormone Assay in Korean Patients with Primary Hyperparathyroidism: Eirie Cho, Jung Mi Chang, Seok Young Yoon, Gil Tae Lee, Yun Hyi Ku, Hong Il Kim, Myung-Chul Lee, Guk Haeng Lee, Min Joo Kim; Endocrinol Metab. 2014;29(4):464-469. Published online December 29, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.4.464

3,530 View
32 Download
8 Web of Science
4 Crossref

Abstract PDF PubReader

Background

The intraoperative parathyroid hormone (IOPTH) assay is widely used in patients with primary hyperparathyroidism (PHPT). We investigated the usefulness of the IOPTH assay in Korean patients with PHPT.

Methods

We retrospectively reviewed the data of 33 patients with PHPT who underwent parathyroidectomy. Neck ultrasonography (US) and ^99mTc-sestamibi scintigraphy (MIBI scan) were performed preoperatively and IOPTH assays were conducted.

Results

The sensitivity of neck US and MIBI scans were 91% and 94%, respectively. A 50% decrease in parathyroid hormone (PTH) levels 10 minutes after excision of the parathyroid gland was obtained in 91% (30/33) of patients and operative success was achieved in 97% (32/33) of patients. The IOPTH assay was 91% true-positive, 3% true-negative, 0% false-positive, and 6% false-negative. The overall accuracy of the IOPTH assay was 94%. In five cases with discordant neck US and MIBI scan results, a sufficient decrease in IOPTH levels helped the surgeon confirm the complete excision of the parathyroid gland with no additional neck exploration.

Conclusion

The IOPTH assay is an accurate tool for localizing hyperfunctioning parathyroid glands and is helpful for evaluating cases with discordant neck US and MIBI scan results.

Citations

Citations to this article as recorded by

Single-Center Experience of Parathyroidectomy Using Intraoperative Parathyroid Hormone Monitoring
Seong Hoon Kim, Si Yeon Lee, Eun Ah Min, Young Mi Hwang, Yun Suk Choi, Jin Wook Yi
Medicina.2022; 58(10): 1464. CrossRef
The natural history and hip geometric changes of primary hyperparathyroidism without parathyroid surgery
Kyong Yeun Jung, A. Ram Hong, Dong Hwa Lee, Jung Hee Kim, Kyoung Min Kim, Chan Soo Shin, Seong Yeon Kim, Sang Wan Kim
Journal of Bone and Mineral Metabolism.2017; 35(3): 278. CrossRef
The utility of the radionuclide probe in parathyroidectomy for primary hyperparathyroidism
MS Lim, M Jinih, CH Ngai, NM Foley, HP Redmond
The Annals of The Royal College of Surgeons of England.2017; 99(5): 369. CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef

Author index